<DOC>
	<DOCNO>NCT00688441</DOCNO>
	<brief_summary>The purpose study evaluate safety effect nasal carbon dioxide treatment Seasonal Allergic Rhinitis</brief_summary>
	<brief_title>The Effect Nasal Carbon Dioxide ( CO2 ) Treatment Seasonal Allergic Rhinitis</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , placebo-controlled , parallel group trial evaluate efficacy safety nasal , non-inhaled administration carbon dioxide ( CO2 ) patient seasonal allergic rhinitis . An estimated 500 patient meet eligibility criterion enrol study approximately 25 site ensure approximately 400 patient randomize complete study .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Able read understand inform consent voluntarily consent sign inform consent form Able comply requirement protocol ( e.g. , complete diary within protocolspecified window ) Minimal 2year history Fall seasonal allergic rhinitis require pharmacotherapy Positive skin test one Fall seasonal allergen ( e.g. , ragweed , birch pollen , etc . ) Females childbearing potential must commit use acceptable method birth control negative pregnancy test History asthma ( mild intermittent ) Acute significant sinusitis upper respiratory infection within 14 day enrollment Existing serious medical condition ( e.g. , severe emphysema ) preclude participation Females pregnant breastfeed and/or plan become pregnant breastfeed study participation within 7 day last study drug administration Initiation immunotherapy change immunotherapy dose within 6 month precede enrollment ( immunotherapy , dose must maintain throughout trial ) Planned travel outside study area duration study period Participation another clinical study within 30 day plan enrollment date duration study Participation previous study Nasal CO2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Double-Blind</keyword>
	<keyword>Multi-Center</keyword>
	<keyword>Placebo-Controlled</keyword>
	<keyword>Phase II</keyword>
	<keyword>Nasal Carbon Dioxide</keyword>
	<keyword>Carbon Dioxide</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Total Nasal Symptom Score</keyword>
	<keyword>RQLQ</keyword>
</DOC>